0001567619-22-004763.txt : 20220216 0001567619-22-004763.hdr.sgml : 20220216 20220216180717 ACCESSION NUMBER: 0001567619-22-004763 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220215 FILED AS OF DATE: 20220216 DATE AS OF CHANGE: 20220216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell James H CENTRAL INDEX KEY: 0001757390 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10670 FILM NUMBER: 22644965 MAIL ADDRESS: STREET 1: 10910 DOMAIN DRIVE, SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HANGER, INC. CENTRAL INDEX KEY: 0000722723 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 840904275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10910 DOMAIN DRIVE STREET 2: SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 BUSINESS PHONE: 512-777-3800 MAIL ADDRESS: STREET 1: 10910 DOMAIN DRIVE STREET 2: SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 FORMER COMPANY: FORMER CONFORMED NAME: HANGER ORTHOPEDIC GROUP INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SEQUEL CORP DATE OF NAME CHANGE: 19890814 FORMER COMPANY: FORMER CONFORMED NAME: CELLTECH COMMUNICATIONS INC DATE OF NAME CHANGE: 19860304 4 1 doc1.xml FORM 4 X0306 4 2022-02-15 0 0000722723 HANGER, INC. HNGR 0001757390 Campbell James H 10910 DOMAIN DRIVE, SUITE 300 AUSTIN TX 78758 0 1 0 0 SVP, Chief Clinical Officer Common Stock 2022-02-15 4 A 0 3692 0 A 46891 D Stock Options (right to buy) 12.77 2027-05-19 Common Stock 27328 27328 D Represents performance shares being issued to the reporting person based on the achievement of performance targets for the period beginning January 1, 2021 and ending on December 31, 2021. These performance shares vest in equal tranches over a four year period, commencing on the first anniversary of the grant date. Consists of (i) unvested restricted shares totaling 3,692 shares of stock from an initial grant of 3,692 shares of restricted stock that begins to vest on March 8, 2022; (ii) unvested restricted shares totaling 4,650 shares of stock from an initial grant of 4,650 shares of restricted stock that begins to vest on March 8, 2022; (iii) unvested restricted shares totaling 3,540 shares of stock from an initial grant of 3,873 shares of restricted stock that begins to vest on March 9, 2021; (iv) unvested restricted shares totaling 4,164 shares of stock from an initial grant of 4,556 shares of restricted stock that begins to vest on March 9, 2021; (v) unvested restricted shares and fully vested shares totaling 3,647 shares of stock from an initial grant of 4,405 shares of restricted stock made on March 8, 2019; [continued in next footnote] (vi) unvested restricted shares and fully vested shares totaling 4,322 shares of stock from an initial grant of 5,220 shares of restricted stock made on March 8, 2019; (vii) unvested restricted shares and fully vested shares totaling 5,114 shares of stock from an initial grant of 6,710 shares of restricted stock made on March 9, 2018; (viii) unvested restricted shares and fully vested shares totaling 3,623 shares of stock from an initial grant of 7,029 shares of restricted stock made on March 8, 2017; (ix) fully vested shares totaling 1,058 shares of stock from an initial grant of 3,000 shares of restricted stock made on October 11, 2016; and (x) unvested restricted shares and fully vested shares totaling 2,025 shares of stock from an initial grant of 6,008 shares of restricted stock made on April 29, 2016. Except as otherwise noted, all remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant. Stock options were granted under the Company's Special Equity Plan and vest 1/3 on each of May 19, 2018, 2019 and 2020. /s/ Jessica Lochmann Allen, Attorney-in-Fact for James H. Campbell 2022-02-16